.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

On the Horizon in NSCLC: Antibody Drug Conjugates

Experts discuss current and investigational antibody drug conjugates (ADCs) in non-small cell lung cancer treatment and how they affect therapy approaches.

EP. 1: ADC Technology and Mechanism of Action

July 13th 2022

Edward S. Kim, MD, MBA, and Alexander Spira, MD, PhD, FACP, provide an overview of antibody-drug conjugates, including mechanism of action, historical milestones in development, and the approved ADCs for non–small cell lung cancer treatment.

EP. 2: ADCs in Non-Small Cell Lung Cancer

July 21st 2022

Alexander Spira, MD, PhD, FACP, and Edward S. Kim, MD, MBA, shift their focus to the use of antibody-drug conjugates in non-small cell lung cancer treatment with a review of ADC clinical trial data.

EP. 3: The Impact of ADCs on Non-Small Cell Lung Cancer Treatment

August 2nd 2022

A discussion on how ADCs affect current standards of care in the non-small cell lung cancer treatment landscape.

EP. 4: Dr. Spira on the Evaluation of Tusamitamab Ravtansine Plus Pembrolizumab in NSCLC

August 3rd 2022

Alexander I. Spira, MD, PhD, FACP, discusses the exploration of the antibody-drug conjugate tusamitamab ravtansine with pembrolizumab in patients with non–small cell lung cancer.

EP. 5: ADCs in NSCLC: Audience Q&A

August 8th 2022

Drs Edward S. Kim and Alexander Spira answer viewer questions on ADCs in non-small cell lung cancer.